Halyard Health Inc. (NYSE:HYH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday. The firm currently has a $41.00 price objective on the stock. Zacks Investment Research’s price target would indicate a potential upside of 11.56% from the stock’s previous close.

According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “

HYH has been the subject of several other reports. Stifel Nicolaus raised their target price on shares of Halyard Health from $37.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, August 4th. Deutsche Bank AG lifted their price target on shares of Halyard Health from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, August 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Halyard Health has a consensus rating of “Buy” and a consensus price target of $38.00.

Halyard Health (NYSE:HYH) traded up 0.93% during midday trading on Monday, reaching $36.75. 234,493 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $34.14 and its 200 day moving average is $33.70. The firm has a market capitalization of $1.72 billion, a P/E ratio of 39.14 and a beta of 1.77. Halyard Health has a 52 week low of $22.76 and a 52 week high of $37.31.

Halyard Health (NYSE:HYH) last posted its earnings results on Wednesday, November 2nd. The company reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.39 by $0.09. Halyard Health had a net margin of 2.80% and a return on equity of 8.63%. The firm earned $398 million during the quarter, compared to the consensus estimate of $387.64 million. During the same period last year, the firm posted $0.52 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, analysts expect that Halyard Health will post $1.91 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in HYH. Bank of Hawaii bought a new stake in Halyard Health during the second quarter worth about $272,000. Chicago Equity Partners LLC bought a new stake in Halyard Health during the second quarter worth about $7,189,000. Confluence Investment Management LLC increased its stake in Halyard Health by 3.4% in the second quarter. Confluence Investment Management LLC now owns 60,951 shares of the company’s stock worth $1,982,000 after buying an additional 1,983 shares during the last quarter. Bank of Montreal Can bought a new stake in Halyard Health during the second quarter worth about $268,000. Finally, Parametrica Management Ltd bought a new stake in Halyard Health during the second quarter worth about $314,000. Hedge funds and other institutional investors own 85.38% of the company’s stock.

Halyard Health Company Profile

Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.

5 Day Chart for NYSE:HYH

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.